Search results for Rgnx

Latest updates for Rgnx

Fresh curated links around RGNX are collected here so marketers can spot useful updates and turn timely ideas into posts faster.

Post angles to try

Share the most useful takeaway for your audience.

Turn one article into a quick practical checklist.

Ask your audience how this shift affects their work.

Turn angles into scheduled posts

Fresh articles and ideas

Recent curated links from global sources. Generate one free draft from any story, then use SocialBu to schedule and refine your content calendar.

seekingalpha.com /3 weeks ago

Regenxbio: 'Hold' On RGX-121 CRL MPS II And RGX-202 DMD Results

Read source

genengnews.com /3 weeks ago

StockWatch: Regenxbio Tumbles Despite Positive Pivotal Data for DMD Gene Therapy Candidate

Investors and analysts concluded Regenxbio's positive data was not encouraging enough to pose a competitive threat to the developer of the first marketed DMD gene therapy, Sarepta...

Read source

fiercebiotech.com /4 weeks ago

Regenxbio reaps pivotal win for Duchenne muscular dystrophy gene therapy

Regenxbio’s gene therapy for Duchenne muscular dystrophy has smashed the primary endpoint of its pivotal trial, securing a win for a biotech that has struggled in recent months und...

Read source

seekingalpha.com /1 week ago

Repligen Has A Cleaner Recovery Angle, But With High Valuation

Read source

biopharmadive.com /4 weeks ago

With new data, Regenxbio to seek FDA approval of Duchenne gene therapy

Though two serious side effects muddied the results, CEO Curran Simpson expressed optimism about a clearance and claimed FDA leadership will have a “mandate on rare disease flexibi...

Read source

investing.com /1 week ago

Form 13G REGENXBIO Inc. For: 4 June

Read source

finance.yahoo.com /1 month ago

RBC Capital Lifts PT on CG Oncology (CGON), Calls PIVOT-006 a Complex Catalyst

Read source

finance.yahoo.com /1 month ago

FDA Accepts Ultragenyx (RARE) BLA for Sanfilippo Syndrome Gene Therapy UX111

Read source

finance.yahoo.com /1 month ago

FDA Accepts Ultragenyx (RARE) BLA for Sanfilippo Syndrome Gene Therapy UX111

Read source

seekingalpha.com /3 weeks ago

NRx Pharmaceuticals, Inc. (NRXP) Q1 2026 Earnings Call Transcript

Read source

seekingalpha.com /1 month ago

Regeneron Pharmaceuticals, Inc. (REGN) Discusses C5 Complement Development Program Focusing on Cemdisiran and Pozelimab...

Read source

cafepharma.com /5 days ago

Argenx

Argenx Anonymous (not verified) Sun, 06/07/2026 - 17:48 field_thread_url https://cafepharma.com/boards/threads/argenx.665212/ board name...

Read source

cafepharma.com /1 week ago

Argenx

Argenx Anonymous (not verified) Sat, 05/30/2026 - 14:41 field_thread_url https://cafepharma.com/boards/threads/argenx.665212/ board name...

Read source

seekingalpha.com /1 month ago

Exagen reaffirms $70M-$73M 2026 revenue guidance as it targets $600-$650 ASP over time

Read source

seekingalpha.com /4 days ago

Nurix Therapeutics, Inc. (NRIX) Discusses Strategic Collaboration for Development and Commercialization of Bexobrutideg...

Read source

seekingalpha.com /4 days ago

Tango Therapeutics, Inc. (TNGX) Discusses Promising Clinical Results for Vopimetostat and Pan-RAS Inhibitor Combination...

Read source

fool.com /2 weeks ago

What to Know About This Fund's $6.6 Million UroGen Sale After a 600% Stock Surge

This biotech firm develops therapies for urothelial cancers, leveraging proprietary delivery technology and a growing clinical pipeline.

Read source

investing.com /1 month ago

Taysha to present preclinical data on Rett syndrome gene therapy

Read source

seekingalpha.com /3 weeks ago

argenx: The FcRn Franchise Is Becoming An Autoimmune Operating System

Read source

seekingalpha.com /4 days ago

Tango Therapeutics, Inc. (TNGX) Discusses Promising Clinical Results for Vopimetostat and Pan-RAS Inhibitor Combination...

Read source

seekingalpha.com /3 weeks ago

Tango Therapeutics: 'Hold' On Combination Strategy Shift Of Vopimetostat

Read source

finance.yahoo.com /1 month ago

Recursion Pharmaceuticals (RXRX) Offers Encouraging Prospects After Setting 2026 Priorities

Read source

fool.com /1 week ago

A New $21 Million Position Signals Confidence in This Post-IPO Drug Developer

This biotechnology firm leverages machine learning to design novel protein therapeutics targeting unmet medical needs.

Read source

investing.com /1 month ago

Arvinas stock gains after Rigel deal for VEPPANU rights

Read source

Turn fresh research into a full content calendar

Use SocialBu to discover ideas, generate post drafts, and schedule them across your social channels.